Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...

Methotrexate is an immunosuppressive agent which blocks DNA synthesis by inhibiting dihydrofolate reductase. It is typically given either as a single weekly dose of 7.5 to 25 mg per week or divided ...

The intracellular polyglutamation of methotrexate (MTX) is emerging as a crucial biochemical process in rheumatoid arthritis (RA) therapy. MTX polyglutamates (MTX-PGs) are metabolites formed by the ...

Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...